Amgen is committed to transforming new ideas and discoveries into medicines for patients with serious illnesses by unlocking the potential of biology. Focused on areas of high unmet medical need, Amgen leverages its expertise in science and innovation to improve health outcomes and dramatically improve people's lives. With a foundation in advanced human genetics and a strategy aimed at developing highly differentiated medicines that address serious diseases, Amgen aims to reduce the social and economic burden of disease.
Amgen's Independent Medical Education (IME) funding supports accredited providers who design and implement educational programs independent of any Amgen influence. The grant goals are to help healthcare professionals attain insights and information that contribute to patient care improvement and medical advancement. IME programs that Amgen funds focus on areas such as unmet clinical, educational, or professional practice needs in therapeutic areas of interest, disease state understanding, diagnosis and treatment approaches, quality of care, access to care, and innovative and biosimilar drug development. Specifically, Amgen supports education across various therapeutic and interest areas including Global Biomedical Data Sciences, Oncology, Bone health, Cardiovascular diseases, Inflammation, Nephrology, Neuroscience, Process Development, and Translational Sciences. Each of these categories includes specific needs like disease awareness, treatment options, and advancements in medicine and technology.